Hcw Biologics Inc (HCWB)

Apr 1, 2025, 4:35 PM EDT - 24 days ago

HCW Biologics Announces 1-for-40 Reverse Stock Split

Mar 28, 2025, 3:30 PM EDT - 4 weeks ago

HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

Mar 6, 2025, 6:55 AM EST - 7 weeks ago

HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements

Feb 3, 2025, 7:15 AM EST - 2 months ago

HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

Jan 15, 2025, 7:00 AM EST - 3 months ago

HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

Dec 23, 2024, 8:10 AM EST - 4 months ago

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

Nov 18, 2024, 9:27 PM EST - 5 months ago

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

Nov 18, 2024, 10:15 AM EST - 5 months ago

Why Is Penny Stock HCW Biologics Surging On Monday?

Nov 18, 2024, 7:00 AM EST - 5 months ago

HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate

Nov 14, 2024, 4:40 PM EST - 5 months ago

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

Aug 23, 2024, 4:30 PM EDT - 8 months ago

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction

Aug 14, 2024, 4:35 PM EDT - 9 months ago

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

May 15, 2024, 4:39 PM EDT - 1 year ago

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

Apr 1, 2024, 4:10 PM EDT - 1 year ago

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

Nov 14, 2023, 7:00 AM EST - 1 year ago

HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights

Nov 8, 2023, 7:30 AM EST - 1 year ago

Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

Nov 1, 2023, 7:30 AM EDT - 1 year ago

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

Sep 6, 2023, 7:30 AM EDT - 1 year ago

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

Aug 11, 2023, 7:00 AM EDT - 1 year ago

HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jun 14, 2023, 7:30 AM EDT - 2 years ago

HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders

May 9, 2023, 7:15 AM EDT - 2 years ago

HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights

Apr 27, 2023, 7:40 AM EDT - 2 years ago

HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan

Apr 13, 2023, 7:15 AM EDT - 2 years ago

HCW Biologics Poster Presentation at AACR Annual Meeting 2023

Apr 3, 2023, 8:13 AM EDT - 2 years ago

A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases

Mar 28, 2023, 4:25 PM EDT - 2 years ago

HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Dec 8, 2022, 7:55 AM EST - 2 years ago

HCW Biologics Enters CRADA with National Cancer Institute

Dec 7, 2022, 7:30 AM EST - 2 years ago

HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform

Nov 8, 2022, 7:00 AM EST - 2 years ago

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting

Nov 7, 2022, 4:45 PM EST - 2 years ago

HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights

Aug 31, 2022, 9:22 AM EDT - 2 years ago

HCW Biologics Inc (HCWB), Quotient Technology (QUOT) – Smith Micro Software And 3 Other Stocks Under $3 Insiders Are Aggressively Buying

SMSI

Aug 29, 2022, 8:58 AM EDT - 2 years ago

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying

CASI HSDT

Aug 12, 2022, 7:00 AM EDT - 2 years ago

HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights

Aug 3, 2022, 7:15 AM EDT - 2 years ago

U.S. Patent Issued to HCW Biologics for Foundational Platform Technology

May 23, 2022, 7:30 AM EDT - 3 years ago

HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022

May 13, 2022, 7:15 AM EDT - 3 years ago

HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

May 5, 2022, 7:30 AM EDT - 3 years ago

HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary and Versatile TOBI™ Platform At the 105th Annual Meeting of the American Association of Immunologists

Apr 19, 2022, 7:33 AM EDT - 3 years ago

HCW Biologics' CEO Hing C. Wong, Ph.D.

Mar 28, 2022, 7:00 AM EDT - 3 years ago

HCW Biologics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights for 2021

Mar 24, 2022, 8:00 AM EDT - 3 years ago

HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-Vest

Jan 24, 2022, 9:22 AM EST - 3 years ago

Masonic Cancer Center To Evaluate HCW Biologics' Bifunctional Fusion Protein In Advanced Cancers

Jan 24, 2022, 7:00 AM EST - 3 years ago

Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics' Novel Bifunctional Fusion Protein

Jan 20, 2022, 9:24 AM EST - 3 years ago

HCW Biologics Lead Candidate Shows Preclinical Anti-Tumor Activity, Reduced Side Effects of Chemo

Jan 20, 2022, 8:00 AM EST - 3 years ago

HCW Biologics Inc. Announces its Lead Product Candidate Shown to Augment Anti-Tumor Activity and Reduce Side Effects of Chemotherapy Regimens

Jan 19, 2022, 8:00 AM EST - 3 years ago

HCW Biologics' Founder and CEO Dr. Hing C. Wong Participating in Cambridge Healthtech Institute's Annual PepTalk Conference 2022

Jan 6, 2022, 7:33 AM EST - 3 years ago

HCW Biologics to Participate in H.C. Wainwright BioConnect Conference January 10 – 13, 2022

Dec 13, 2021, 7:31 AM EST - 3 years ago

HCW Biologics' Founder and CEO Dr. Hing C. Wong Named Weaver H.

Nov 12, 2021, 7:00 AM EST - 3 years ago

HCW Biologics Reports Third Quarter Financial Results and Recent Business Highlights

Oct 28, 2021, 7:00 AM EDT - 3 years ago

HCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic HCW9218 for Pancreatic Cancer

Oct 27, 2021, 7:00 AM EDT - 3 years ago

HCW Biologics Announces Appointment of Two New Members to Board of Directors

Aug 24, 2021, 7:32 AM EDT - 3 years ago

HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218 as Novel, Bifunctional Cancer Immunotherapeutic